Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?

Authors Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I

Received 4 September 2013

Accepted for publication 4 September 2013

Published 23 October 2013 Volume 2013:8(1) Pages 4043—4044

DOI https://doi.org/10.2147/IJN.S53962

Checked for plagiarism Yes

Ciprian Tomuleasa, Andrei Cucuianu, Mihaela Aldea, Ioana Berindan-Neagoe

Research Center of Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

We have read with great interest the study of Kim et al, recently published in the International Journal of Nanomedicine.1 The physicians from South Korea describe the anti-tumor efficacy of sorafenib in cholangiocarcinoma, a malignancy with a dismal prognosis and refractory to most chemotherapy options. Surgery is the only curative option, but is limited to only a small number of cases due to the late diagnosis.2 This emphasizes the need to develop new approaches for such cases and the first potential new option is the tyrosine kinase inhibitor sorafenib, already proven to improve the therapeutic ratio of hepatocellular carcinoma, as according to Llovet et al.3 But unlike hepatocellular carcinoma, cholangiocarcinomas are epithelial cancers with a highly developed desmoplastic stroma due to the interaction between the cancer cell and the cancer associated fibroblasts (CAFs), as well as the macrophages, and the natural killer (NK) cells.4 This tumor microenvironment makes it difficult for a chemotherapy drug to reach the cancer cell and be efficient, which partially explains the reason why Kim et al1 developed a sorafenib-coated stent, that can be placed inside the biliary tree and deliver the drug continuously.

View original paper by Kim and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts

Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisoiu V, Frinc I, Zdrenghea M, Tomuleasa C

OncoTargets and Therapy 2017, 10:5047-5051

Published Date: 19 October 2017

The use of rotation to fentanyl in cancer-related pain

Dima D, Tomuleasa C, Frinc I, Pasca S, Magdo L, Berindan-Neagoe I, Muresan M, Lisencu C, Irimie A, Zdrenghea M

Journal of Pain Research 2017, 10:341-348

Published Date: 9 February 2017

In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice

Berce C, Lucan C, Petrushev B, Boca S, Miclean M, Sarpataki O, Astilean S, Buzoianu A, Tomuleasa C, Bojan A

International Journal of Nanomedicine 2016, 11:4261-4273

Published Date: 1 September 2016

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy

Petrushev B, Boca S, Simon T, Berce C, Frinc I, Dima D, Selicean S, Gafencu GA, Tanase A, Zdrenghea M, Florea A, Suarasan S, Dima L, Stanciu R, Jurj A, Buzoianu A, Cucuianu A, Astilean S, Irimie A, Tomuleasa C, Berindan-Neagoe I

International Journal of Nanomedicine 2016, 11:641-660

Published Date: 15 February 2016

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation

Zaharie F, Cojocneanu-Petric R, Muresan M, Frinc I, Dima D, Petrushev B, Tanase A, Berce C, Chitic M, Berindan-Neagoe I, Pileczki V, Irimie A, Tomuleasa C

International Journal of Nanomedicine 2015, 10:4897-4899

Published Date: 31 July 2015

Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease

Tomuleasa C, Petrushev B, Vedean M, Irimie A, Zaharie F, Rosu AM, Dima D, Cucuianu A

International Journal of General Medicine 2015, 8:93-95

Published Date: 2 March 2015

Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies

Kojima S, Cucuianu A, Takahashi Y, Berindan-Neagoe I, Florian IS, Dima D, Tomuleasa C

International Journal of Nanomedicine 2014, 9:3247-3248

Published Date: 4 July 2014

MRI-based identification of undifferentiated cells: looking at the two faces of Janus

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A

International Journal of Nanomedicine 2014, 9:865-866

Published Date: 11 February 2014

Readers of this article also read:

Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy

Wang H, Wang L, Wuxiao ZJ, Huang HQ, Jiang WQ, Li ZM, Lu Y, Xia ZJ

OncoTargets and Therapy 2015, 8:2589-2599

Published Date: 14 September 2015

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Skull base metastasis from papillary thyroid carcinoma: a report of three cases

Tunio MA, Al Asiri M, Al-Qahtani KH, Aldandan S, Riaz K, Bayoumi Y

International Medical Case Reports Journal 2015, 8:127-131

Published Date: 25 June 2015

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M

OncoTargets and Therapy 2015, 8:1149-1156

Published Date: 22 May 2015

Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads

Schroyen S, Adam S, Jerusalem G, Missotten P

Clinical Interventions in Aging 2015, 10:117-125

Published Date: 31 December 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Application of liposomal technologies for delivery of platinum analogs in oncology

Liu D, He C, Wang AZ, Lin W

International Journal of Nanomedicine 2013, 8:3309-3319

Published Date: 26 August 2013

Multidisciplinary care in pediatric oncology

Cantrell MA, Ruble K

Journal of Multidisciplinary Healthcare 2011, 4:171-181

Published Date: 30 May 2011

Pegylated liposomal doxorubicin in the management of ovarian cancer

Gabriella Ferrandina, Giacomo Corrado, Angelo Licameli, et al

Therapeutics and Clinical Risk Management 2010, 6:463-483

Published Date: 29 September 2010